Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
Status:
Completed
Trial end date:
2017-08-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see
what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.